Dostarlimab for neoplasm metastasis

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 3 trial. Large late-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 21 Jan 2022: Trial registered, NCT05201547
  2. 15 Apr 2022: Trial started, NCT05201547

The trials

NCT05201547: Endometrial Cancer Patientes MMR Deficient Comparing Chemotherapy vs Dostarlimab in First Line

State
Under way
Phase
Phase 3
People
260 planned
Started
15 Apr 2022
Primary completion
1 Oct 2026
Arms
Arm A: Dostarlimab 500 mg, every 3 weeks, 4 cycles and then 1000 mg every 6 weeks
Results
None posted
  1. 21 Jan 2022: Trial registered
  2. 15 Apr 2022: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 3 trial

About the treatment

Also known as TSR-042 or Dostarlimab.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.